Fotemustine and interferon α2b in metastatic malignant melanoma

[1]  D. Betticher,et al.  Dacarbazine and interferon‐α 2a in advanced malignant melanoma: high response rate and prolongation of response duration occur in different patient subpopulations , 1995, Melanoma research.

[2]  W. Tilgen.  Malignant Melanoma: Current Therapeutic Concepts , 1995 .

[3]  M. Glabbeke,et al.  Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC‐Melanoma Cooperative Group (MCG) , 1995, Melanoma research.

[4]  D. Schadendorf,et al.  In vitro sensitivity of human melanoma cells to chemotherapeutic agents and interferons , 1994, Melanoma research.

[5]  G. Castello,et al.  Role of interferons in the therapy of melanoma , 1992, Melanoma research.

[6]  P. Hersey,et al.  Treatment of advanced malignant melanoma with recombinant interferon alfa‐2a in combination with DTIC: long‐term follow‐up of two phase II studies , 1991, British journal of haematology.

[7]  J. Kirkwood.  Studies of interferons in the therapy of melanoma. , 1991, Seminars in oncology.

[8]  C. Falkson,et al.  Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  N. Mulder,et al.  Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma. , 1990, British Journal of Cancer.

[10]  D. Schaid,et al.  Disseminated malignant melanoma and recombinant interferon: analysis of seven consecutive phase II investigations. , 1990, The Journal of investigative dermatology.

[11]  M. Namer,et al.  Final report of the french multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases , 1990, Cancer.

[12]  J. Kirkwood,et al.  Interferon α-2a and dacarbazine in melanoma , 1990 .

[13]  R. Benjamin,et al.  A prospective evaluation of a triple‐drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma , 1989, Cancer.

[14]  S. Gundersen,et al.  Interferon in combination with vinblastine in advanced malignant melanoma. A phase I–II study , 1989, Cancer.

[15]  M. Ef,et al.  Systemic chemotherapy for metastatic melanoma. , 1988 .

[16]  M. Mastrangelo,et al.  Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. , 1987, Cancer treatment reports.

[17]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[18]  E. Bröcker,et al.  Interferon α2b and Fotemustine in Patients with Disseminated Melanoma , 1995 .